Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Bearish
2
Neutral
7
Bullish
5
Bearish
18
Neutral
7
Bullish
21
Bearish
16
Neutral
0
Bullish
16
Discovery themes featuring this stock
Orchid Pharma Limited is a vertically integrated pharmaceutical company focused on development, manufacture and global commercialisation of APIs and finished dosages, with particular strength in cephalosporin antibiotics, sterile injectables and an emerging branded/licensing platform led by its new Orchid Antimicrobial Solutions (AMS) division and recently acquired European assets.
Q3 FY26 financials show stress: standalone sales fell to INR207 crore (-5% YoY) and 9M sales to INR574 crore (-16% YoY), EBITDA margins compressed to 6% in Q3 from 17% a year ago, gross margin declined to 31% versus prior ~43%, and Q3 reported a small loss (PAT negative INR6 crore) driven by industry-wide antibiotic price erosion and inventory adjustments.
Orchid is pivoting strategically—launching Exblifep commercially in Europe and GCC, progressing licensing discussions across more than ten countries, and growing AMS; these moves convert Orchid from a pure API/exporter into a royalty/licensing and differentiated sterile/FDF player, potentially changing medium-term revenue mix and margin profile.
The 7ACA project is central to cost competitiveness: Orchid reports pilot-scale fermentation yields met, major equipment deliveries underway, and a September mechanical completion target, positioning the company to reduce dependency on imported intermediates and improve gross margins once commercial production begins.
Product pipeline and commercialization catalysts are visible: Orchid is progressing Cefiderocol FDF (API already manufactured, FDF production targeted December 2026), advancing US filings for Teflaro and Avycaz with partner discussions underway, and increasing R&D spend to about 1.5% of sales to support FDF launches for regulated markets.
Pharmaceuticals & Biotechnology
Pharmaceuticals
5,011 Cr
Moderate Risk
184.7
36.7
-2.5
3.9
1,120.00
471.30
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stock
Orchid Pharma Ltd (ORCHPHARMA) is currently trading at 992.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Orchid Pharma Limited is a vertically integrated pharmaceutical company focused on development, manufacture and global commercialisation of APIs and finished dosages, with particular strength in cephalosporin antibiotics, sterile injectables and an emerging branded/licensing platform led by its new Orchid Antimicrobial Solutions (AMS) division and recently acquired European assets. Q3 FY26 financials show stress: standalone sales fell to INR207 crore (-5% YoY) and 9M sales to INR574 crore (-16% YoY), EBITDA margins compressed to 6% in Q3 from 17% a year ago, gross margin declined to 31% versus prior ~43%, and Q3 reported a small loss (PAT negative INR6 crore) driven by industry-wide antibiotic price erosion and inventory adjustments. Orchid is pivoting strategically—launching Exblifep commercially in Europe and GCC, progressing licensing discussions across more than ten countries, and growing AMS; these moves convert Orchid from a pure API/exporter into a royalty/licensing and differentiated sterile/FDF player, potentially changing medium-term revenue mix and margin profile. The 7ACA project is central to cost competitiveness: Orchid reports pilot-scale fermentation yields met, major equipment deliveries underway, and a September mechanical completion target, positioning the company to reduce dependency on imported intermediates and improve gross margins once commercial production begins. Product pipeline and commercialization catalysts are visible: Orchid is progressing Cefiderocol FDF (API already manufactured, FDF production targeted December 2026), advancing US filings for Teflaro and Avycaz with partner discussions underway, and increasing R&D spend to about 1.5% of sales to support FDF launches for regulated markets.
Over the past 52 weeks, Orchid Pharma Ltd has traded between a low of ₹471.30 and a high of ₹1,120.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Orchid Pharma Ltd has a market capitalization of approximately 5,010.54. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Orchid Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 184.65 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 5,010.54 Cr, Orchid Pharma Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Orchid Pharma Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Orchid Pharma Ltd is 184.65. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Yes. The NCLT Chennai Bench sanctioned the scheme, with the order pronounced on June 05, 2026 and uploaded on the NCLT website on June 11, 2026.
Orchid Pharma signed an exclusive licensing and supply agreement under which Pharmasyntez will register and commercialise Exblifep in Russia, while Orchid supplies the finished dosage form.
Orchid and Pharmasyntez signed a licensing and supply agreement to commercialise Exblifep in Russia, subject to approval by the Ministry of Health of the Russian Federation.
Orchid says it is in advanced talks to out-license enmetazobactam in the United States and expects a deal to be finalised in the near term.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
951.05 | 5,401 Cr | 38.47 | 4.95 | 0.21 | 12.92 | 14.30 | 7.67 | ||
992.00 | 5,011 Cr | 184.65 | 3.89 | 0.00 | 2.11 | 2.48 | 1.10 | ||
461.00 | 4,916 Cr | 37.26 | 4.12 | 0.22 | 10.82 | 16.48 | 9.03 | ||
3016.80 | 4,818 Cr | 43.93 | 7.96 | 0.82 | 19.03 | 24.66 | 14.52 | ||
149.40 | 4,385 Cr | 30.06 | 2.44 | 0.67 | 7.65 | 10.29 | 5.32 | ||
1258.40 | 4,358 Cr | — | 6.28 | 0.08 | -10.66 | -6.48 | -6.55 | ||
1657.35 | 4,067 Cr | 41.60 | 4.97 | 0.00 | 11.39 | 15.94 | 9.99 | ||
| Median: 7 Co. | — | 992.00 | 4,818 Cr | 40.03 | 4.95 | 0.21 | 10.82 | 14.30 | 7.67 |
Regulatory/Compliance Filing
Orchid Pharma notifies BSE/NSE that Whole Time Director Mridul Dhanuka will attend investor roadshows in Singapore on July 29-31, 2026. Company states no Unpublished Price Sensitive Information will be shared.
Regulatory/Compliance Filing
Orchid Pharma Ltd informs that Mr. Mridul Dhanuka, Whole Time Director, will attend investor roadshow (physical group meets) in Singapore on July 29-31, 2026. No unpublished price sensitive information will be shared.
